CagriSema Phase 3: 22.7% Weight Loss Data
Decision brief
Answer first · skim in under a minute
Novo Nordisk’s CagriSema Phase 3 program produced 22.7% mean weight loss in REDEFINE 1, reinforcing the program as a major obesity catalyst. This plan frames the results, the next clinical milestones, and why BD and investor teams should track them.
CagriSema Phase 3 data from REDEFINE 1 put Novo Nordisk’s dual agonist firmly on the obesity catalyst calendar. Adults on cagrilintide 2.4 mg plus semaglutide 2.4 mg lost a mean 22.7% of body weight at 68 weeks when adherent, versus 2.3% on placebo.
Contents9 sections
Key Takeaways
- REDEFINE 1 randomized 3,417 adults; adherent-use analysis showed 22.7% mean weight loss with CagriSema at 68 weeks versus 2.3% placebo.
- NEJM’s treatment-policy estimand reported −20.4% versus −3.0% placebo (difference −17.3 percentage points).
- Only 57% of patients reached the highest CagriSema dose in Novo’s December 20, 2024 headline results, per the SEC-filed company announcement.
- CagriSema remains investigational; filing timing and REDEFINE program readouts are the next investor watches.
What did CagriSema Phase 3 deliver in REDEFINE 1?
REDEFINE 1 is a 68-week Phase 3 trial of once-weekly subcutaneous CagriSema versus cagrilintide 2.4 mg, semaglutide 2.4 mg, and placebo. Novo’s December 20, 2024 Form 6-K reported mean baseline weight of 106.9 kg and superiority versus placebo on the primary endpoint.
On the adherence estimand, CagriSema reached 22.7% mean weight loss versus 11.8% with cagrilintide, 16.1% with semaglutide, and 2.3% with placebo. About 40.4% of CagriSema patients lost 25% or more of body weight versus 0.9% on placebo.
How do the NEJM numbers differ from the headline 22.7%?
The New England Journal of Medicine publication reports the treatment-policy estimand consistent with intention-to-treat: −20.4% with cagrilintide–semaglutide versus −3.0% placebo at week 68. Gastrointestinal adverse events were common (79.6% vs 39.9% placebo) and mostly mild to moderate.
Investors should cite both estimands. The 22.7% figure answers “if everyone stayed on drug.” The 20.4% figure answers “what happened in the randomized population regardless of adherence.”
Why is CagriSema Phase 3 a catalyst for Novo Nordisk?
CagriSema combines an amylin analogue with a GLP-1 receptor agonist. Superiority versus semaglutide 2.4 mg monotherapy in the adherent analysis supports a differentiation thesis versus Wegovy-class agents, even though manufacturing and dose-escalation realities still constrain uptake.
- 3,417 participants randomized across four arms
- 68-week primary analysis window
- NCT05567796 on ClinicalTrials.gov
- GlobeNewswire and PR Newswire copies mirror the SEC 6-K headline statistics
What did Novo say about dose attainment?
Martin Holst Lange noted the weight-loss profile showed superiority over both monotherapies “even though only 57% of patients reached the highest CagriSema dose,” according to the December 2024 company announcement filed with the SEC. That detail is load-bearing for modeling: real-world titration may further separate label claims from trial maxima.
Novo also said it plans to explore additional weight-loss potential based on REDEFINE 1 insights. Those follow-on design choices—not the single 22.7% print—will shape 2026–2027 regulatory narratives.
What remains unproven after REDEFINE 1?
CagriSema is still investigational. Public Phase 3 obesity efficacy does not equal FDA approval, a labeled indication, or guaranteed supply. Cardiovascular outcomes, long-term maintenance after stop, and head-to-head commercial positioning versus tirzepatide-class agents are not settled by REDEFINE 1 alone.
Do not invent submission dates, PDUFA goals, or peak-sales figures that Novo has not disclosed in allowlisted filings.
Related NovaPharma coverage
- Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
- Novo Nordisk supply of Wegovy stabilizes as new capacity comes online
- Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends
Frequently Asked Questions
What did CagriSema Phase 3 show in REDEFINE 1?
In REDEFINE 1, once-weekly CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) achieved 22.7% mean weight loss at 68 weeks if all people adhered to treatment, versus 2.3% with placebo, in 3,417 randomized adults with obesity or overweight and comorbidities.
What is the treatment-policy estimand for CagriSema?
When evaluated regardless of adherence, NEJM reported about 20.4% mean weight reduction with cagrilintide–semaglutide at 68 weeks versus 3.0% with placebo (estimated difference −17.3 percentage points).
What is the ClinicalTrials.gov ID for REDEFINE 1?
REDEFINE 1 is registered as NCT05567796 on ClinicalTrials.gov and was published in the New England Journal of Medicine.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CagriSema.
Unlock full calendar →Merck & Co. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- RYBREVANT® Access and Reimbursement Guide Overview — Explore key insights on RYBREVANT® reimbursement and access strategies for NSCLC treatment.…
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…